One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis

doi:10.1186/s12933-022-01673-8

CASIA OpenIR > 多模态人工智能系统全国重点实验室 > 互联网大数据与信息安全

	One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis
	Wang,Hong 1; Xie,Xiaoya 2; Zu,Quannan3 ; Lu,Ming 3; Chen,Rongfa 4; Yang,Zhiren 4; Gao,Yongqiang 1
发表期刊	Cardiovascular Diabetology
	2022-10-28
卷号	21 期号:1 页码:10
通讯作者	Wang,Hong(iriswh2014@163.com)
摘要	AbstractBackgroundDiabetes mellitus (DM) and cardiovascular diseases often co-exist. Today, percutaneous coronary intervention (PCI) is the preferred revascularization procedure for majority of patients with coronary artery disease. Polymer-free amphilimus-eluting stents (AES) represent a novel elution technology in the current era of drug-eluting stents. In this analysis, we aimed to systematically compare the cardiovascular outcomes which are associated with polymer-free amphilimus-eluting stents (AES) versus the durable polymer zotarolimus-eluting stents (ZES) for the treatment of patients with DM.MethodsHttp://www.ClinicalTrials.gov, EMBASE, Web of Science, MEDLINE, Cochrane database and Google Scholar were searched for publications comparing polymer-free AES versus durable polymer ZES in patients with DM. Selective cardiovascular outcomes were assessed. Statistical analysis was carried out by the latest version of the RevMan software. Risk ratio (RR) with 95% confidence interval (CI) was used to represent the data analysis.ResultsFour studies with a total number of 1795 participants with DM whereby 912 patients were assigned to be revascularized by the polymer-free AES and 883 patients were assigned to be revascularized by the durable polymer ZES were included in this analysis. In patients with DM, at one year, polymer-free AES were associated with significantly lower risk of major adverse cardiac events (MACEs) (RR: 0.69, 95% CI: 0.54–0.88; P?=?0.002) and target lesion failure (TLF) (RR: 0.66, 95% CI: 0.48–0.91; P?=?0.01) compared to durable polymer ZES. However, there was no significant change in all-cause mortality (RR: 0.79, 95% CI: 0.51–1.22; P?=?0.28), cardiac death and the other cardiovascular outcomes. Similar risk of total stent thrombosis (RR: 1.13, 95% CI: 0.60–2.13; P?=?0.70), including definite stent thrombosis (RR: 1.12, 95% CI: 0.38–3.31; P?=?0.84), probable stent thrombosis (RR: 0.87, 95% CI: 0.37–2.09; P?=?0.76), possible stent thrombosis (RR: 1.19, 95% CI: 0.50–2.87; P?=?0.69) and late stent thrombosis (RR: 1.00, 95% CI: 0.17–5.72; P?=?1.00) as between polymer-free AES and durable polymer ZES in patients with DM.ConclusionsAt 1?year follow-up, polymer-free AES were associated with significantly lower MACEs and TLF compared to durable polymer ZES in these patients with DM, without any increase in mortality, stent thrombosis and other cardiovascular outcomes. However, this analysis is only based on a follow-up time period of one year, therefore, future research should focus on the long term follow-up time period.
关键词	Diabetes mellitus Polymer-free Amphilimus-eluting stents Durable polymer zotarolimus-eluting stents Percutaneous coronary intervention Cardiovascular outcomes Target lesion failure Major adverse cardiac events Stent thrombosis
DOI	10.1186/s12933-022-01673-8
关键词[WOS]	CLINICAL-OUTCOMES ; DISEASE ; EVEROLIMUS
收录类别	SCI
语种	英语
资助项目	Guangxi Key Research and Development Program ; Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project[S2017077] ; Guangxi Nanning Qingxiu District Science and Technology Development Project[2014S06]
项目资助者	Guangxi Key Research and Development Program ; Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project ; Guangxi Nanning Qingxiu District Science and Technology Development Project
WOS研究方向	Cardiovascular System & Cardiology ; Endocrinology & Metabolism
WOS类目	Cardiac & Cardiovascular Systems ; Endocrinology & Metabolism
WOS记录号	BMC:10.1186/s12933-022-01673-8
出版者	BioMed Central
引用统计
文献类型	期刊论文
条目标识符	http://ir.ia.ac.cn/handle/173211/50105
专题	多模态人工智能系统全国重点实验室_互联网大数据与信息安全
通讯作者	Wang,Hong
作者单位	1.The People’s Hospital of Guangxi Zhuang Autonomous Region; Department of Cardiology 2.Macau University of Science and Technology 3.Tianjin University; College of Management and Economics 4.Chinese Academy of Sciences; The State Key Laboratory Management and Control for Complex Systems, Institute of Automation
推荐引用方式 GB/T 7714	Wang,Hong,Xie,Xiaoya,Zu,Quannan,et al. One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis[J]. Cardiovascular Diabetology,2022,21(1):10.
APA	Wang,Hong.,Xie,Xiaoya.,Zu,Quannan.,Lu,Ming.,Chen,Rongfa.,...&Gao,Yongqiang.(2022).One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis.Cardiovascular Diabetology,21(1),10.
MLA	Wang,Hong,et al."One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis".Cardiovascular Diabetology 21.1(2022):10.